MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study
EASL LiverTree™. Harrison S. 04/13/18; 210658 Topic: Thyroid hormone analogs
Dr. Stephen Harrison
Dr. Stephen Harrison
Learning Objectives
After viewing this presentation the participant will be able to:
- Learn about effects of a THR-B agonist MGL-3196 in patients with NASH (safety/efficacy)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies